Sinomab Bioscience Limited (3681)

Overview

SinoMab BioScience Limited is a cutting-edge biopharmaceutical company primarily focused on the research, development, manufacturing, and commercialization of monoclonal antibody (mAb)-based biologics for treating immunological diseases. Founded in 2001 and based in Pak Shek Kok, Hong Kong, the company has extended its operations across Mainland China and the Cayman Islands. SinoMab is dedicated to advancing healthcare by targeting a range of conditions such as rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and non-Hodgkin's lymphoma (NHL), among others. Its robust pipeline of innovative therapeutics is designed to meet the unmet needs of patients worldwide.

Products and Services

• SM03 (Anti-CD22 Monoclonal Antibody)

  SinoMab's flagship product, SM03, is a pioneering anti-CD22 monoclonal antibody, currently in Phase III clinical trials for the treatment of rheumatoid arthritis (RA). This first-in-target mAb is also being studied across various clinical stages for other significant immunological diseases, including systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL), showing the company's commitment to leveraging biologic therapies for autoimmune and inflammatory conditions.

• SN1011 (Bruton's Tyrosine Kinase Inhibitor)

  SN1011 represents a significant advancement in the treatment of pemphigus as it undergoes Phase II clinical trials. Additionally, this Bruton's tyrosine kinase inhibitor is being tested in Phase I clinical trials aimed at treating multiple sclerosis, systemic lupus erythematosus (SLE), and neuromyelitis optica spectrum disorder (NMOSD), showcasing the breadth of SinoMab's research in addressing complex autoimmune diseases.

• Preclinical Stage Products
  • SM17 - Focused on the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis, underscoring the company's endeavor into respiratory and skin conditions.
  • SM06 - A potential therapeutic for rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), NMOSD, and Sjogren's syndrome (SS), highlighting the versatility of SinoMab's product pipeline in targeting a variety of immunological diseases.
  • SM09 - Being developed for non-Hodgkin's lymphoma (NHL) and rheumatoid arthritis (RA), this further exemplifies the company's commitment to cancer and autoimmune diseases.
  • TNF2 - Aimed at treating a spectrum of autoimmune diseases, this underlines SinoMab's focus on expanding its portfolio into a broad array of therapeutic areas.